Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report published on Friday, Benzinga reports.

Several other analysts also recently weighed in on LXRX. StockNews.com upgraded Lexicon Pharmaceuticals to a sell rating in a research report on Wednesday, May 1st. SVB Leerink started coverage on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 30th. They set an outperform rating and a $5.00 price objective for the company. Finally, Leerink Partnrs restated an outperform rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th.

Lexicon Pharmaceuticals Trading Up 5.2 %

Lexicon Pharmaceuticals stock traded up $0.09 during midday trading on Friday, reaching $1.83. The stock had a trading volume of 2,334,439 shares, compared to its average volume of 4,336,164. Lexicon Pharmaceuticals has a 52-week low of $0.92 and a 52-week high of $3.73. The company has a fifty day moving average of $2.10 and a 200 day moving average of $1.75. The firm has a market cap of $450.62 million, a price-to-earnings ratio of -2.20 and a beta of 1.38. The company has a quick ratio of 15.56, a current ratio of 15.58 and a debt-to-equity ratio of 0.35.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 108.54% and a negative net margin of 8,311.12%. The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.68 million. On average, analysts anticipate that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Lexicon Pharmaceuticals in the third quarter worth about $64,000. Commonwealth Equity Services LLC lifted its position in shares of Lexicon Pharmaceuticals by 160.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 24,400 shares during the period. TIAA Trust National Association bought a new position in shares of Lexicon Pharmaceuticals during the third quarter valued at approximately $29,000. Swiss National Bank increased its holdings in Lexicon Pharmaceuticals by 4.4% during the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 10,300 shares during the period. Finally, KWB Wealth bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth approximately $62,000. Institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.